USFDA issues 2 observations to Natco Pharma for Vizag facility

The company focuses primarily on niche therapeutic areas and complex products. Natco market and distribute its products in over 40 countries.

569
Form 483
Form 483

Last Updated on October 10, 2024 by The Health Master

Hyderabad: Natco Pharma Limited has announced the completion of a regulatory inspection from the United States Food and Drug Administration (USFDA) for its formulation facility in Ramky Special Economic Zone (SEZ), near Visakhapatnam (Vizag), India, which was conducted from January 30th, 2023, to February 3rd, 2023.

Two observations were made about the facility’s written production process control procedure and investigation procedure at the conclusion of the inspection.

Natco Pharma Limited is a vertically integrated and R&D-focused pharmaceutical company engaged in the development, manufacturing, and marketing of finished dosage formulations (“FDF”) and active pharmaceutical ingredients (“APIs”).

The company focuses primarily on niche therapeutic areas and complex products. Natco market and distribute its products in over 40 countries.

Natco sells its FDF products in the United States, India, Europe, and the rest of the world (“RoW”).

In the API segment, the company has the capabilities to develop and manufacture products with multi-step synthesis, semi-synthetic fusion technologies, high-potency APIs, and peptides.

The company has seven manufacturing facilities spread across India with modern research laboratories, capabilities in New Drug Development, etc.

USFDA issues Form 483 with zero observation to Solara Active Pharma Sciences Vizag Facility

USFDA issues Form 483 with 9 observations to Indoco Remedies, Goa

USFDA issues Form 483 with 8 observations to Jubilant

USFDA issues Form 483 with 8 observations to Lupin

USFDA issues Form 483 with 10 observations to Aurobindo Pharma

USFDA issues Form 483 with 3 Observations to Alkem

NABL alerts all Testing Laboratories regarding misrepresentation of NABL symbol

Lux level in Industry (Pharma, Cosmetics, Homeopathy & Medical Devices)

NPPA fixed Ceiling price of 1 scheduled formulation: February 2023

Drug recall: 5,720 tubes of Clobetasol Propionate Cream recalled due to this reason

Aerosols in Cosmetics

NPPA revised Ceiling price of 53 scheduled formulations: February 2023

Pharma companies restrained from making Diabetes drug

India to spend $79.6 million to strengthen Drug Regulatory system

Latest IPC Alert – Indian Pharmacopoeia Commission

Latest Notifications regarding Pharmaceuticals

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news